



**Diagnostics & Precision Medicine Summit 2016**  
 June 21, 2016

Company Presentation/Poster Application

Company Name	
Life Sciences Sector	<input checked="" type="checkbox"/> Diagnostics <input type="checkbox"/> Biotech <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other (specify):
Commercial Focus/Therapeutic Area	<i>Respiratory</i>
Company Description (max 50 words)	<i>Please attach</i>
Company Development/Commercial Stage	
Product Name (if applicable)	<i>Functional Respiratory Imaging</i>
Product Description – Include value and advancements that the product brings to Precision Medicine (max 100 words)	<i>Please attach</i>
Funding Status	<i>Private Equity</i>
Presentation/Poster Objectives	<input checked="" type="checkbox"/> Partnering <input type="checkbox"/> Funding <input type="checkbox"/> Other (specify):
Contact Name/Title	<i>Lieven Nuyttens, CEO</i>
Contact Information	Email:  

**Thank**

**RUTGERS**

**JaD**

**Lieven Nuyttens, MSc, MBA**  
 C.E.O., US Division

Tel: (+1) 646 250 9286  
 Lieven.Nuyttens@fluidda.com

**United States – FLUIDDA, Inc.**  
 675 US Highway One  
 North Brunswick, NJ 08902  
 United States

**Europe – FLUIDDA NV**  
 Groeningenlei 132  
 2550 Kontich • Belgium  
 Tel +32 3 450 87 20  
 info@fluidda.com

Please print, fill out and submit this form

## COMPANY INFORMATION

FLUIDDA is the world leader in the field of Functional Respiratory Imaging (FRI) research and development. The company's proprietary FRI technology offers pharmaceutical companies and healthcare providers a unique entry point into personalized medicine for patients suffering from respiratory diseases and sleep-related breathing disorders. Implementation of FRI in the clinical practice creates significant added value to the current healthcare standard in the respiratory field.

- FLUIDDA was founded in 2005. Its Head Office is located in Kontich Belgium, with subsidiaries in India and the US.
- Flow simulations are combined with CT scans to provide a unique sensitive tool for phenotyping patients and monitoring the efficacy of novel respiratory drugs.

## PRODUCT INFORMATION

Functional Respiratory Imaging (FRI) is a novel quantification imaging methodology to measure lung and airway structural and functional parameters. FRI uses low-dose high-resolution volumetric computerized tomography (HRCT) scans and quantitative imaging technology based on fluid dynamics to model airflow and measure structural and functional characteristics of the respiratory system.

FRI-based biomarkers are intended to be used as an indicator for biological response to therapeutic intervention in patients with idiopathic pulmonary fibrosis (IPF), and to provide quantifiable predictions about drug performance contributing to clinical proof of concept and dose selection.

FRI technology provides detailed measurement, visualization and evaluation of the lungs and airways, both regionally and its totality, allowing for a detailed understanding of lung health and, in the case of progressive diseases like IPF, lung deterioration. Therefore, FRI measurements can be used in drug development to:

- evaluate disease stage and progression,
- evaluate biological response to therapeutic intervention,
- provide quantifiable predictions about drug performance, and
- contribute to clinical development decisions.